Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
254
-
Total 13F shares, excl. options
-
69.1M
-
Shares change
-
-1.18M
-
Total reported value, excl. options
-
$4.1B
-
Value change
-
-$79.7M
-
Put/Call ratio
-
1.72
-
Number of buys
-
136
-
Number of sells
-
-125
-
Price
-
$59.30
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q2 2020
339 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q2 2020.
NovoCure Ltd - Common Stock (NVCR) has 254 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.1M shares
of 112M outstanding shares and own 61.7% of the company stock.
Largest 10 shareholders include FMR LLC (10.4M shares), BAILLIE GIFFORD & CO (7.9M shares), VANGUARD GROUP INC (7.47M shares), Capital World Investors (5.3M shares), BlackRock Inc. (4.3M shares), Capital International Investors (3.49M shares), CREDIT SUISSE AG/ (2.2M shares), RENAISSANCE TECHNOLOGIES LLC (2M shares), WELLINGTON MANAGEMENT GROUP LLP (1.77M shares), and Darsana Capital Partners LP (1.7M shares).
This table shows the top 254 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.